BOSTON -- Beth Israel Deaconess Medical Center (BIDMC) geneticist John Rinn, PhD, whose research has helped uncover a new class of RNA, has been named to this year's "Brilliant 10" list of top young scientists by
Popular Science magazine. The list appears in the magazine's November issue, which is on newsstands today.
Rinn is a member of BIDMC's Department of Pathology and is an Assistant Professor of Pathology at Harvard Medical School.
Dubbed "The Rule Shredder" by the magazine, Rinn has a long history of bucking convention - and upending the way biologists think about the human genome. In 2003, as a graduate student at Yale, Rinn first discovered large intervening non-coding RNA, or lincRNA, a new class of molecule that has been shown to play a leading role in the human genome - though until recently had been dismissed as "genomic junk" despite Rinn's assertions to the contrary. Click here to read the full article.
Popular Science notes, "[Rinn] silenced his critics in 2007 when he showed that one of the [lincRNA molecules] serves a vital function in human cells. He dubbed it HOTAIR, a wry nod to the fact that so many scientists thought his field of research was full of it. The molecule delivers proteins to a crucial cluster of genes and helps regulate immune response, cancer growth and fat- and stem-cell production, among other things."
"John Rinn is revolutionizing the way we think about the human genome," says BIDMC Chief of Pathology Jeffrey Saffitz, MD, PhD. "The potential implications for understanding disease are profound. We are particularly pleased that John has chosen to work in a pathology department, where scientific advances can be translated to improve patient care."
Earlier this year, in the scientific journal
Nature, Rinn described his discovery of more than 1,000 functional lincRNA molecules in mammals. Using a novel means of analysis, he and his colleagues uncovered a set of genetic elements that could one day lead to new avenues for developing therapeutics, particularly in cancers.
Last month, Rinn's "outside-the-box" thinking was further rewarded when he received a grant from the National Institutes of Health (NIH) as part of their New Innovator Awards, one of three new programs designed to encourage investigators to explore bold ideas that have the potential to catapult fields forward and speed the translation of research into improved health. Rinn's $2.6 million NIH grant will further his investigations into lincRNAs and their potential to help stem disease. And, early this year, the audacious nature of Rinn's work earned him a prestigious Damon Runyon Innovation Award, made in support of "high-risk, high-reward" research.
As Rinn notes, "If we can solve the code of how each lincRNA knows what part of the genome to regulate, we might be able to exploit this mechanism to engineer lincRNAs that 'fix' a damaged cancer genome by targeting and silencing overactive cancer cells, thereby restoring the genome back to its proper identity."
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks in the top four in National Institutes of Health funding among independent hospitals nationwide. BIDMC is a clinical partner of the Joslin Diabetes Center and a research partner of the Harvard/Dana-Farber Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information visit